FONDATION-IPSEN
Stem cells in adults are the source of the body’s regenerative potential. Dividing and differentiating to replace dying or damaged cells. Discovering the specific signals that activate stem cells holds substantial promise for repairing damaged organs. Recently developed techniques for producing large numbers of stem cells in the laboratory are enabling the investigation of basic stem-cell biology and the creation in vitro models of diseases. Cells are being prepared for transplantation into the body and the relationship between healthy and cancer-forming stem cells is being examined. At the Fondation IPSEN’s annual Colloque Médecine et Recherche in the Endocrine Interactions series, an international panel of speakers reviewed how these potent new techniques are being applied to the control of hormone production by the hypothalamus and pituitary gland, the master neuro-endocrine organs that regulate processes ranging from growth, metabolic control and appetite to sleep, stress and aging. Advancing understanding of this system and our ability to repair it will substantially benefit human health and well-being. This meeting, was held in Paris on December 7th , 2015, was organised by Donald Pfaff (The Rockefeller University, New York, USA ) and Yves Christen (Fondation IPSEN, Paris, France ).
Many of the body’s functions are regulated by endocrine hormones, secreted by glands such as the thyroid, pancreas and adrenals. These are controlled by the pituitary gland, located just below the brain, which in turn is governed by the hypothalamus, in the base of the brain, in response to signals it receives from other parts of the brain. This complex neuro-endocrine regulatory system ensures homeostasis by integrating different body functions and their responses to environmental signals. For example, the response to stressful situations involves the central nervous system, the neuro-endocrine and the immune system. Failure either to activate or terminate these responses may result in anxiety, depression and eating disorders (Alon Chen, Max Planck Institute, Munich, Germany ).
Damage to the hypothalamus and pituitary can result from accident, radiation or tumour growth, with profound consequences that include sleep disturbances, weight gain, abnormal stress responses and age-related conditions. Current hormone replacement treatment is costly and has side effects. Stem-cell therapy, whether by transplanting stem cells grown in vitro or activating intrinsic stem cells offers a much more satisfactory alternative (Pfaff; Karine Rizzoti, MRC National Institute for Medical Research, London, UK ).
Many adult tissues contain nests of stem cells, which are undifferentiated and retain the capacity to proliferate. Each cell division creates one offspring with stem-cell properties and the other, known as a progenitor cell, that can differentiate into a variety of cell types. Studying stem and progenitor cells is providing the information needed for using stem cells to repair damaged human tissues (Inna Tabansky, The Rockefeller University, New York, USA ). This includes understanding the molecular pathways that determine the fate of each cell, how tissues maintain and repair themselves, and the role of cell turnover in organ function. Another important aspect is to discover how tissues are organised in three dimensions, so that transplanted cells can be successfully integrated into living tissue (Tabansky; Rizzoti).
Proliferation and differentiation are triggered by chemical signals from within or outside the tissue, few of which have been identified. Recently discovered stem cells in the pituitary seem to be activated mainly in pathological states: in mice that lack a certain type of hormone-producing cell, functional replacement cells were generated by stimulating this stem-cell population (Hugo Vankelekom, University of Leuven, Leuven, Belgium ). A complex of local signals, some secreted by the stem cells themselves, and environmental influences yet to be identified determine whether stem cells remain quiescent or divide. A signaling pathway well-known in developmental biology promotes proliferation in vitro in a subset of stem cells that give rise to hormone-producing cells (Cynthia Andoniadou, King’s College, London, London, UK ). Differentiation of progenitor cells depends on epigenetic mechanisms, such as chromatin remodeling, that activate genes specific to each type of cell. The choice of differentiation pathway determines the fate of the pituitary-cell progenitors, in this case whether they become cells that secrete melanocyte-stimulating hormone or ones producing adrenocorticotropic hormone (Jacques Drouin, Institut de Recherches Cliniques de Montréal, Montréal, Canada ).
In one part of the hypothalamus, cells known as tanycytes have the properties of neural stem cells and progenitors. In response to a high-fat diet and low levels of the hormone leptin, which signals satiety, they differentiate into neurons. Learning more about these signals may contribute to the treatment of diabetes and obesity (Seth Blackshaw, Johns Hopkins University School of Medicine Baltimore, USA ).
Like all things in life, stem cells have their dark side: under certain conditions, they can seed tumour formation. Various animal models are being used to establish what causes this potential and to understanding why and how tumours form in the pituitary. This is essential to safeguard against stem cells used for transplantation developing into tumours (Vankelekom; Andoniadou; Rizzoti).
Stem cells in culture are also offering new opportunities for unravelling the cellular mechanisms of disease an approach being successfully applied to the study of depression (Patricia Zunszain, Institute of Psychiatry, London, UK ). Stem-cells from the human hippocampus, a part of the brain involved in memory formation, differentiate in response to anti-depressant drugs. On the other hand, the birth of new neurons is suppressed by inflammatory molecules, which are an integral part of depression resulting from stress, and the stress hormone cortisol. In time, it should be possible to tailor treatment for individual patients by determining their inflammatory status.
But perhaps the ultimate goal of stem-cell research is to transplant well-defined cells into humans to replace cells that malfunction as a result of genetic mutation, accident or degenerative processes. The recent discovery that skin fibroblasts taken from a patient can be reprogrammed in vitro, so that they revert to stem or progenitor cells, has been a huge step forward. These induced pluripotent stem cells (iPSC) can be produced in large numbers and because they match the patient’s genotype, complications of graft rejection are avoided. Signal molecules and transcription factors are being identified that can reliably direct these cells to differentiate into the required cell types (Tabansky).
One exciting approach is to grow three-dimensional ‘organoids’ in culture for studying the complex of positional signals involved in generating organ structure. They also be used as models for disease and drug screening, as well as providing tissue for transplantation (Hidetaka Suga, Nagoya Univesrity Hospital, Nagoya, Japan ; Rizzoti). Floating three-dimensional aggregates have been created: one has properties of specific areas of the hypothalamus, including hormone release, and another of pituitary cells releasing adrenocorticotropic hormone. When this cultured tissue is transplanted into mice lacking pituitaries, their hormone levels, physical activity and survival are restored (Suga).
Most promising of all, human mid-brain dopamine neurons, which degenerate in Parkinson’s disease, have successfully been generated in vitro. They are functionally integrated when transplanted into animal models of the disease and regulatory approval for testing in human patients is awaited (Lorenz Studer, Memorial Sloan Kettering Cancer Centre, New York, USA ). The methods employed provide a blueprint for generating progenitor cells for the pituitary and hypothalamic neurons that release corticotrophin-releasing hormone and thyroid-stimulating hormone (Studer; Viviane Tabar, Memorial Sloan Kettering Cancer Centre, New York, USA ). Progenitors for myelin-producing oligodendrocytes also are being created, for repairing the diffuse demyelination that results from radiation damage and causes motor and cognitive deficits (Tabar).
About the Fondation Ipsen
Established in 1983 under
the aegis of the Fondation de France, the mission of the Fondation Ipsen
is to contribute to the development and dissemination of scientific
knowledge. The long-standing action of the Fondation Ipsen aims at
fostering the interaction between researchers and clinical
practitioners, which is indispensable due to the extreme specialization
of these professions. The ambition of the Fondation Ipsen is to initiate
a reflection about the major scientific issues of the forthcoming years.
It has developed an important international network of scientific
experts who meet regularly at meetings known as Colloques Médecine et
Recherche
, dedicated to six main themes: Alzheimer's disease,
neurosciences, longevity, endocrinology, the vascular system and cancer
science. Moreover the Fondation Ipsen has started since 2007 several
meetings in partnership with the Salk Institute, the Karolinska
Institutet, the Massachusetts General Hospital, the Days of Molecular
Medicine Global Foundation as well as with the science journals Nature,
Cell and Science. The Fondation Ipsen produced several hundred
publications; more than 250 scientists and biomedical researchers have
been awarded prizes and research grants.
You can find other
information about Fondation Ipsen
on our website:
www.fondation-ipsen.org
View source version on businesswire.com: http://www.businesswire.com/news/home/20151211005591/en/
Contact:
For further information, please contact:
Isabelle de
Segonzac, Image Sept
E-mail : isegonzac@image7.fr
Tel.
: +33 (0)1 53 70 74 70
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Civil Air Patrol Expands Fleet With 15 New Cessna Aircraft to Support Lifesaving and Community Missions15.12.2025 17:00:00 CET | Press release
Latest deliveries bring CAP’s Cessna fleet to more than 500 aircraft nationwide Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, announced today that Civil Air Patrol (CAP), the world’s largest operator of Cessna aircraft, is strengthening its national mission capabilities with an order for 15 additional piston-engine aircraft, including seven Cessna Skyhawk 172 and eight Cessna Skylane 182 models scheduled for delivery throughout 2026. The order follows recent deliveries of an additional two Cessna Skylane and one Cessna Turbo Stationair HD aircraft, expanding CAP’s fleet to more than 500 Cessna aircraft nationwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215613573/en/ Delivery of an additional two Cessna Skylane and one Cessna Turbo Stationair HD aircraft joins CAP’s fleet of more than 500 Cessna aircraft nationwide. Cessna aircraft are designed and produced by Textron Aviation. “Civil Air Patrol’s miss
Winston & Strawn and Taylor Wessing UK to Combine, Creating a Premier Transatlantic Law Firm15.12.2025 16:52:00 CET | Press release
Winston Taylor to build on shared vision and culture in establishing a transatlantic powerhouse for major litigation, critical transactions, strategic IP, and private wealth Winston & Strawn and Taylor Wessing’s UK-led business announced today their intention to combine, creating a premier transatlantic law firm that would operate under a new shared name, Winston Taylor. The combination responds to increasing client demand for seamlessly integrated US–UK–EU counsel for the businesses, people, and markets driving capital and innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215914957/en/ The combination once final will unite two international firms with more than 400 years of combined history, complementary strengths, and a common vision to meet clients’ evolving global needs. The combined firm will include more than 1,400 lawyers, establishing one of the largest transatlantic firms whose footprint is primarily in
Despite Barriers, Financial Institutions are Clear About AI's Greatest Impact15.12.2025 16:32:00 CET | Press release
HTEC Finds AI is Everywhere in FSI, but Scaling Across the Enterprise Remains the Industry's Biggest Hurdle HTEC, a global AI-first provider of software and hardware design and engineering services, today released The State of AI in Financial Services & Insurance 2025, a first industry subset of its global research report in AI. This publication offers one of the clearest views to date into how financial institutions are adopting and scaling artificial intelligence. This industry-focused report analyzes insights from 250 C-suite leaders within financial services and insurance, drawn from HTEC’s broader global study of 1,529 C-suite executives—including CIOs, CTOs, CDOs, CPOs, CFOs, COOs, CEOs and CSOs—across Saudi Arabia, the UAE, the United Kingdom, the United States, Germany and Spain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215790717/en/ Executive Summary: The State of AI in Financial Services and Insurance 2025
Align Partners Sends Second Public Shareholder Letter to Coway, Urging Announcement of Revised Value-up Plan by January 30, 202615.12.2025 15:54:00 CET | Press release
Align identifies an inefficient capital structure and a sharp contraction in shareholder returns as core drivers of Coway’s undervaluationThe letter outlines seven key measures to strengthen capital allocation and governanceAlign urges Coway to announce a more concrete and enhanced Value-up Plan by January 30, 2026 Align Partners Capital Management Inc. (“Align Partners”), a shareholder of Coway Co., Ltd. (“Coway”) since 2023 holding more than 4% of the Company’s outstanding shares through funds it manages or advises, announced that it has sent a second public shareholder letter to Coway’s Board of Directors. The letter calls for measures to address the company’s chronic undervaluation and enhance shareholder value. Align Partners has requested that Coway announce a revised corporate Value-up Plan reflecting these proposals by January 30, 2026. In the letter, Align Partners assessed Coway’s February 2025 plan as insufficient to address Coway’s persistent undervaluation and urged the Bo
Marathon Asset Management Provides Junior Capital Financing to EXALTA Group15.12.2025 15:00:00 CET | Press release
Marathon Asset Management (“Marathon”), a leading global credit manager with more than $24 billion of assets under management, is pleased to announce the closing of a junior capital financing to EXALTA Group (“EXALTA” or the “Company”), a portfolio company of Montagu. Marathon led the financing that supported the formation of EXALTA through the strategic merger of three Montagu-owned companies including Intech, Resolve Surgical Technologies, and Tyber Medical. The transaction marks one of many successful transactions for Marathon’s European Credit business in the healthcare sector, where the firm has a knowledge-based advantage with a dedicated Healthcare Finance business and specialized medical advisory board providing sector insight to middle market companies. EXALTA is a global leader in orthopaedic contract design and manufacturing for spine, trauma, extremities, sports medicine and enabling technology providing comprehensive solutions to OEMs within the medical technology industry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
